Redcliffe Labs has announced the launch of the Elecsys® AMH Plus blood test, in collaboration with Roche Diagnostics India, to support the timely identification of Polycystic Ovarian Morphology (PCOM) and aid in the diagnosis of Polycystic Ovary Syndrome (PCOS). This addresses a pressing need, given that global estimates suggest up to 70% remain undiagnosed.
Nearly 1 in 5 women of reproductive age in India are affected, and to resolve this concern, Redcliffe Labs, with the Elecsys®AMH Plus, is redefining this experience.
Instead of an invasive scan, a simple blood draw measures Anti-Müllerian Hormone (AMH), a biomarker strongly linked to PCOM and present in nearly 4 out of 5 PCOS cases in India. This test eliminates the drawbacks of transvaginal ultrasound (TVUS).
The Elecsys® AMH Plus test is backed by strong global and local validation. International guidelines released in 2023 now recognize AMH as a reliable alternative to ultrasound for assessing PCOM, while in India, FOGSI’s Good Clinical Practice Recommendations have endorsed its use in aiding PCOS diagnosis.
Large clinical studies, including APHRODITE and HARMONIA, further confirm its accuracy - at a cut-off of 3.2 ng/mL, the test delivers 89% sensitivity and 85% specificity. Together, these endorsements position the Elecsys® AMH Plus test as a trusted, evidence-based solution for clinicians and a breakthrough in accessible care for women.
